About iDNA

OUR MISSION

Up to now, medical doctors have only been able, in most cases, to extend the lives of people diagnosed with lung cancer. This is because lung cancer is almost always diagnosed at a late stage where survival rates are very low: nine out of ten people diagnosed with a stage 4 lung cancer tumour will not be alive in five years. There have been big advancements in both medication and treatment in recent decades, but late stage diagnosis still means these advancements were mainly life-extending and not live-saving.

New opportunities

Now there is a chance for change. A new line of research brings real life-saving solutions within reach. After two decades of research, the NELSON Randomized Controlled Clinical Trial has shown that using a screening method based on Computed Tomography (CT) actually leads to reductions in mortality: 24% for men and up to 59% for women. CT is a medical imaging technology normally used in hospitals to diagnose patients who are presented with certain symptoms that provide a clear suspect in terms of disease. The NELSON study has shown that this technology can also be used as a preventive examination for the early detection of the disease, even though a patient may have no specific complaints. In this way, medical doctors can spot a tumour in an early stage when treatment can really save lives. When caught early, the stats actually reverse: nine out of ten people diagnosed will be alive after five years.

Just imagine what this innovative research could mean in practice. With 338,000 annual deaths in Europe alone, more than 81,000 lives could be saved yearly, which would make lung cancer screening the single most effective healthcare innovation in this area. Now is the time to bring this research into practice and to ensure that it is accessible to those who benefit. This is the mission of the institute for DiagNostic Accuracy (iDNA). We are determined to make it happen.

OUR TEAM

oudkerk@i-dna.org
+31 (0)50 211 03 48

Prof. M. Oudkerk, MD, PhD

Prof. Oudkerk is responsible for the Research & Development of iDNA.

He is professor of Radiology at the University of Groningen, Chief Scientific Officer of the Institute for Diagnostic Accuracy- iDNA (formerly of the Center of Medical Imaging NORTH EAST NETHERLANDS , NWO research Center of Exellence) and the principal investigator for Radiology of the NELSON lung cancer detection study, the Robinsca cardiovascular screening study and the 4Lungrun Horizon 2020 study. Founder and past president of the European Society of Cardiac Radiology and former Chairman of Radiology departments of DDHK Erasmus MC Rotterdam and University Medical Center Groningen. Prof. Oudkerk has a broad insight into new imaging modalities, algorithms and strategies. He is ranked as one the most influential researchers in Radiology in Europe (2019). For his research work he received prestigious grants such as EU Horizon 2020, ERC advanced grant, Royal Academy of Sciences of the Netherlands (KNAW), Ministry of Science and Technology of China (MOST), NWO, KWF, NKB grants etc.

He is lead investigator of the NELSON lung cancer detection study, the  ROBINSCA study for coronary disease detection, NELCIN B3 study in China focusing on lung cancer , coronary artery disease and pulmonary disease  in one imaging test. Prof. Oudkerk was invited as a member of the medical advisory board of Siemens AG Germany for development of the first continuous rotating spiral CT and has been part of this board until the development of the current volume multi-detector CT scanners pushing forward the need for higher temporal resolutions in CT scanning comparable with EBT. With his research team he initiated the field of CT coronary imaging; Prof. Oudkerk is inspiring many (inter-)national students to start their PhD research in his Institute, resulting in several PhD defenses per year.

Prof Oudkerk published more than 555 peer reviewed articles, is cited over 20,000 times with an H-index >74 (Scopus). Key publications in NEJM, Lancet, Thorax, Circulation, JACC, Eur Heart, Radiology, Lancet Oncology, etc.

Erik Jippes, PhD, MBA

jippes@i-dna.org
+31 (0)6 21 55 19 99

Erik Jippes, PhD, MBA

Erik Jippes is responsible for the day-to-day operation of iDNA.

Erik’s background working in a medical academic environment, and with medical imaging in particular, enables him to understand and act on the complexities in hospital environments. This is of great importance for implementing lung cancer screening programmes.

Erik has a Master of Business Administration and holds a PhD in social networks and innovation processes in healthcare. He worked for more than 14 years at a University Medical Center and was responsible for several large public–private partnerships, pre- and post-award project management for funding support (H2020, national and regional grants), and charity fundraising.

He was manager of several large-scale population-based early detection and screening trials in lung cancer and cardiovascular diseases.

In his spare time Erik likes to travel with his wife and three children, and he loves to play beach volleyball.

dvortsin@i-dna.org
+31 (0)6 24 21 71 13

Evgeni Dvortsin, MSc

Evgeni Dvortsin is a health economist and healthcare entrepreneur, responsible for leading the development and execution of the long-term strategies of iDNA.

His background as a founder of Asc Academics — a globally operating health economics and market access consultancy — provides an excellent knowledge foundation in cost-benefit analyses in healthcare. This is of the utmost importance for the implementation of lung cancer early detection and screening programs. In addition, Evgeni co-founded the General Practitioners Research Institute (GPRI), which aims to improve the lives of patients by facilitating participation in real world evidence generation studies.

Evgeni has a background as a pharmacist and pharmaceutical scientist at the University of Groningen, and, in his rare moments of spare time, he enjoys everything related to basketball.

chen@i-dna.org
 +31 (0)6 42 29 99 19

Jie Hui Chen, MBA

Jie Hui Chen is responsible for the strategic partnerships and relations with Asia. She is also responsible for the day-to-day operation for iDNA Asia.

Jie Hui is an entrepreneur who has more than 15 years of experience in bridging Asian and Dutch companies. She studied Asian Business Studies and obtained an MBA certificate from national Sun Yat Sen University in Taiwan. She is an expert in Chinese language and culture and has an extensive network within Asia. Since 2016, Jie Hui has been the liaison manager between hospitals in China and the Netherlands for several large-scale population-based early detection and screening studies in lung cancer and cardiovascular diseases.

Moreover, she has a personal motivation; her grandmother in China passed away from lung cancer. This inspires her to give her best every day for iDNA.

Jie Hui likes to travel and explore new cultures with her husband and two children.

Boudewijn H. Breens, MSc

breens@i-dna.org
+31 (0)6 20 30 50 50

Boudewijn H. Breens, MSc

Boudewijn Breens has over 15 years of experience in (non-dilutive and dilutive) financing private and public organizations active within the Life Sciences and Health sector (LSH). He is well-versed for creating and retain a durable impact, including implementing a clear long-term strategic focus. This is endorsed by his creativity, energy (and humor) and a proven business development track record in executing numerous projects throughout the broad spectrum of challenges within LSH.

He joined iDNA in 2019 with the ambition to set-up and implement the financial, strategic and business development activities within Europe and China. Prior to iDNA, Boudewijn worked as a senior business developer within the Life Sciences and Health team of PNO Consultants. In the past he worked within the Corporate Finance and Capital Markets department of Fortis Bank, currently ABN AMRO. He supported the execution of a wide range of finance and strategic transactions in the (public and private) biotech sector within Europe and the USA. He previously also held several positions within Zilveren Kruis, a Dutch national health insurance company and PRA International, an international CRO. Solving financing and operational challenges were his main pillars.

After his education, he was an investment manager at BioPartner Start-Up ventures, a pre-seed financing boutique, investing in start-up companies within the Life Sciences sector in the Netherlands. Boudewijn Breens received his master’s degree in Biomedical Sciences at the VU in Amsterdam, with a main focus on Biomedical entrepreneurship, e.g. how to capitalize on an optimal R&D strategy by means of a successful IPO.

fuhler@i-dna.org
+31 (0)6 27 31 30 02

Sebastiaan Fuhler, MSc

Sebastiaan Fuhler completed his Master of Biomedical Sciences at the University of Groningen and chose iDNA because he wanted to make academic discoveries and innovations available to society. His passion for medical sciences drives his ambition to make screening for lung cancer a reality. Sebastiaan uses his academic background and creativity in his role as consultant. He brings a healthy dose of humour to the work floor and has the ability to put things in a different perspective.

Kees Horchner, MSc

horchner@i-dna.org
+31 (0)6 22 69 83 42

Kees Horchner, MSc

Kees Horchner is a financial advisor with extensive experience in the private financing of complex projects including healthcare, education, infrastructure, and real estate.

He has extensive work experience in over 40 countries, mainly in the EMEA region.

His specialties are within public–private partnerships, project finance, and hospital financing.

Barend van Lieshout, MSc

vanlieshout@i-dna.org
+31 (0)6 53 8558 86

Barend van Lieshout, MSc

Barend van Lieshout works on healthcare projects that involve business cases, investment decisions and the financing of healthcare institutions. He analyses projections regarding the financial future and provides management advice. All his projects start with a strategic and a market analysis.

Barend tends to dig deeper into the financial condition of the organization to ensure that the best approach is effectively implemented. Basically, it’s getting results making Barend very happy.

Haonan Zhang, LL.M.

h.zhang@i-dna.org
+31 (0)6 16 95 24 59

Haonan Zhang, LL.M.

Haonan is an experienced Legal Counsel with a demonstrated history of working in legal industry. He is skilled in drafting international contracts, dispute management, legal reasoning, and team cooperation. Graduating from Leiden University with a Master of Laws degree (LL.M.) in International Civil and Commercial Law, he can combine his international eyesight with legal expertise in mitigating various risks in international transactions while promoting business cooperation in the meantime.

Robert Janz, PhD

After graduating as Theoretical Biologist at the University of Groningen in The Netherlands, Robert Janz has, professionally, mainly been active in the area of ICT and Academia. Since 1981 until May 2018 he has been employed at the Computing Centre (now named the Centre for Information Technology) of the University of Groningen. Starting as lecturer, then as Head of the Network Department, in 1995 he became the Chief Technical Officer of the Centre for Information Technology (CIT) of the University (6.000 staff and 27.000 students).

In 2005 he switched to the position of senior ICT consultant. In this position the focus was on initiating and implementing large multi-partner ICT projects with the University of Groningen as one of the leading partners, such as the ICT part of the LOFAR project (Radio Astronomy), the Groningen Internet Exchange, the Big Data project TARGET and the municipal wireless network of the city of Groningen. In the international context Robert has been active in implementing large ICT projects in the Higher Education and Research sector in Africa and Central Asia. The focus in these projects has gradually moved to developing sustainable NRENs in sub-Sahara Africa (Zambia, Mali and Mozambique), Central Asia (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan), including the regional academic network CAREN, and Afghanistan.

Most recently Robert is working for iDNA in a large project to, virtually, merge globally distributed databases of chest CT scans and make this sensitive data available for a global group of medical researchers.

Sunyi Zheng, MSc

Sunyi Zheng is an AI data engineer of iDNA. He has a strong background in both medical and technical sciences, being dedicated to computer-aided diagnoses in Big-3 diseases (lung cancer, cardiovascular disease, and chronic obstructive pulmonary disease).
He is also a highly motivated PhD candidate at the University of Groningen. His PhD project is focused on computer vision for early detection of lung cancer in chest CT scans. Sunyi is interested in deep learning techniques and applying them in clinical practice.

The multi-disciplinary iDNA team includes radiologists, pulmonologists, oncologists, and technical physicians, and has the knowledge and capacity to answer your questions.

Dianne Ramaker

ramaker@i-dna.org

Dianne Ramaker

Dianne Ramaker is a master student Biomedical Sciences at the University of Groningen. She is currently specializing herself within the “Science, Business and Policy” track.

As an intern, her focus is on investigating the attitude of smokers and ex-smokers towards lung screening and includes setting up the optimal pricing model.

Marijn Riemsma

riemsma@i-dna.org

Marijn Riemsma

Marijn Riemsa is a master student Biomedical Sciences at the University of Groningen. She is currently specializing herself within the “Science, Business and Policy” track.

As an intern, her focus is on investigating different recruitment approaches for lung cancer screening and the psychological and socio-economical factors involved.

Koen de Iongh

iongh@i-dna.org

Koen de Iongh

Koen de Iongh is a master student Biomedical Sciences at the University of Groningen. He is currently specializing himself within the “Science, Business and Policy” track.

As an intern, his focus is on the potential opportunities and cost-effectiveness of lung cancer screening in Europe.


OUR SOLUTIONS